North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management

Ali Alikhan, Christopher Sayed, Afsaneh Alavi, Raed Alhusayen, Alain Brassard, Craig Burkhart, Karen Crowell, Daniel B. Eisen, Alice B. Gottlieb, Iltefat Hamzavi, Paul G. Hazen, Tara Jaleel, Alexa B. Kimball, Joslyn Kirby, Michelle A. Lowes, Robert Micheletti, Angela Miller, Haley B. Naik, Dennis Orgill, Yves Poulin

Research output: Contribution to journalArticlepeer-review

237 Scopus citations

Abstract

Hidradenitis suppurativa is a severe and debilitating dermatologic disease. Clinical management is challenging and consists of both medical and surgical approaches, which must often be combined for best outcomes. Therapeutic approaches have evolved rapidly in the last decade and include the use of topical therapies, systemic antibiotics, hormonal therapies, and a wide range of immunomodulating medications. An evidence-based guideline is presented to support health care practitioners as they select optimal medical management strategies and is reviewed in this second part of the management guidelines. A therapeutic algorithm informed by the evidence available at the time of the review is provided.

Original languageEnglish (US)
Pages (from-to)91-101
Number of pages11
JournalJournal of the American Academy of Dermatology
Volume81
Issue number1
DOIs
StatePublished - Jul 2019

All Science Journal Classification (ASJC) codes

  • Dermatology

Fingerprint

Dive into the research topics of 'North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management'. Together they form a unique fingerprint.

Cite this